Investor
JOHNSON & JOHNSON
CIK 0000200406 · filed 2026-05-13 · SEC filing
13F book
$652.4M
Positions
16
1 new · 2 sold
Largest name
39.6%
Protagonist Therapeutics, Inc · PTGX
Est. mark
$100.3M
Price effect on 15 names still held. Flow −$3.02M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics, Inc | PTGX | 2.45M | $258.1M | 39.6% | $44.2M | Held |
| Nanobiotix | — | 5.62M | $173.6M | 26.6% | $43.6M | Held |
| Meiragtx Hldgs Plc | — | 6.64M | $57.5M | 8.8% | $4.72M | Held |
| Rapport Therapeutics, Inc. | RAPP | 1.78M | $55.8M | 8.6% | $1.7M | Held |
| CVRx, Inc. | CVRX | 4.02M | $38.1M | 5.8% | $9.5M | Held |
| Contineum Therapeutics, Inc. | CTNM | 1.98M | $25.8M | 4.0% | $3.23M | Held |
| Legend Biotech Corp | LEGN | 814.6K | $14.7M | 2.3% | −$2.97M | Held |
| Xencor Inc | XNCR | 748.1K | $9.02M | 1.4% | −$2.43M | Held |
| Procept Biorobotics Corp | PRCT | 357.9K | $8.95M | 1.4% | −$2.31M | Held |
| Fate Therapeutics Inc | FATE | 3.38M | $4.05M | 0.6% | $734.6K | Held |
| Neumora Therapeutics, Inc. | NMRA | 1.85M | $3.61M | 0.6% | $295.9K | Held |
| Rallybio Corp | RLYB | 152.9K | $1.37M | 0.2% | — | New |
| Vor Biopharma Inc. | VOR | 53.7K | $958.6K | 0.1% | $255.8K | Held |
| Standard Biotools Inc. | LAB | 312K | $286.8K | 0.0% | −$112.5K | Held |
| Nano-X Imaging Ltd. | NNOX | 83.6K | $189.7K | 0.0% | −$44.3K | Cut−$255.1K |
| Adicet Bio, Inc. | ACET | 22.8K | $155.1K | 0.0% | −$36.7K | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.